Physician profile
Daniel Vincent Arnold
NPI 1679764773
$2,452.62
in general payments reported to CMS, 2019-2025
23 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $107 · 2021: $48.03 · 2022: $124 · 2023: $311 · 2024: $575 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $453.77 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $296.07 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $249.38 | 2019-2025 | Arexvy, Shingrix |
| Pfizer INC. | $232.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $193.75 | 2019-2025 | |
| Abbott Laboratories | $135.57 | 2023 | Freestyle Libre 2 |
| Abbvie INC. | $124.32 | 2022-2025 | |
| Exact Sciences Corporation | $111.74 | 2023-2024 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $110.12 | 2025 | Onpattro |
| Phathom Pharmaceuticals, INC. | $80.36 | 2024-2025 | Voquezna |
| Eisai INC. | $79.34 | 2025 | |
| Boston Scientific Corporation | $67.43 | 2019-2023 | Watchman Access System |
| Lilly USA, LLC | $64.21 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $45.74 | 2023-2024 | |
| Verona Pharma, INC. | $43.61 | 2025 | Ohtuvayre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $34.02 | 2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.18 | 2025 | Xifaxan |
| Inspire Medical Systems, INC. | $21.42 | 2025 | Inspire |
| Lucid Diagnostics INC. | $19.65 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.41 | 2022 | |
| Merck Sharp & Dohme LLC | $16.29 | 2019 | |
| Viatris Specialty LLC | $16.20 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $15.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.